TIL News and Press, Instil Bio Inc. From 11/14/23

2023-11-14 02:18:36 ET More on Instil Bio Seeking Alpha’s Quant Rating on Instil Bio Historical earnings data for Instil Bio Financial information for Instil Bio For further details see: Instil Bio Non-GAAP EPS of -$0.16 misses by $0.01

DALLAS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today reported its third quarter 2023 fin...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

Instil Bio Inc. (TIL) is expected to report $-0.14 for Q3 2023

2023-08-14 09:53:11 ET Instil Bio press release ( NASDAQ: TIL ): Q2 GAAP EPS of -$0.14. As of June 30, 2023, Instil had cash, cash equivalents, restricted cash and marketable securities of $202.9 million, which consists of $21.8 million in cash and cash equi...

ITIL-306, first CoStAR-TIL in clinical development, anticipated to start clinical trial ITIL-306-202 in 2H 2023 Initial data from ITIL-306-202 clinical trial anticipated in 2024 ITIL-306 operational in Manchester, UK manufacturing facility with additional process improvements ...

Presented data showing that folate receptor α (FRα)-CoStAR enhanced activity of TILs against autologous NSCLC, ovarian, and renal tumors ITIL-306, first CoStAR-TIL in clinical development, anticipated to resume clinical study in 2H 2023 Initial clinical data from ITI...

2023-05-11 09:51:16 ET Instil Bio press release ( NASDAQ: TIL ): Q1 GAAP EPS of -$0.44. As of March 31, 2023, Instil had cash, cash equivalents, restricted cash and marketable securities of $223.9 million, which consists of $27.4 million in cash and cash e...

ITIL-306 phase 1 study anticipated to receive CTA clearance from UK MHRA in 2H ’ 2023 Anticipate initial clinical data from ITIL-306 phase 1 program in 2024 Cash runway beyond 2026 DALLAS, May 11, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”...

2023-03-31 09:19:44 ET Instil Bio press release ( NASDAQ: TIL ): Q4 GAAP EPS of -$0.41 in-line. As of December 31, 2022, Instil had $260.9 million in total cash and cash equivalents and marketable securities, comprised of $43.7 million in cash and cash equiv...